Corcept Therapeutics Incorporated CORT

Buffalo Mid Cap Discovery Fund's Q2 2026 investor letter highlights Corcept Therapeutics as a meaningful contributor to relative performance after shares benefited from improved investor confidence in its commercial execution and pipeline opportunities. Corcept closed at $118.51 on Sept. 24, 2026, and has risen 4.07% in the past month and 41.30% over the last 12 months, with a $12.81 billion market cap and a 52-week range of $28.66–$126.38. The fund notes leadership in Health Care and gains in AI-related tech, semiconductors, and AI infrastructure helped overall results, with Corcept's performance aided by its pipeline prospects. The letter also notes that Corcept is not among the 40 most popular hedge-fund stocks (about 30 funds held it in Q2, down from 41), suggesting potential upside tied to execution and pipeline. Improved investor confidence in Corcept's commercial execution and pipeline opportunities could modestly lift near-term sentiment and perception, though no concrete milestones are detailed.

Corcept Therapeutics announced a planned leadership transition: Sean Maduck, President of Endocrinology, will retire and be replaced by Justin Gunn, who starts full duties October 1 and will join the executive team reporting to CEO Joseph Belanoff. Maduck will remain as a senior commercial advisor during the transition. Gunn, who joined Corcept in July 2024 as VP of Sales and Commercial Learning for Oncology, built a new field sales and training organization for Lifyorli, Corcept’s treatment for platinum-resistant ovarian cancer launched with nab-paclitaxel. Belanoff praised Gunn’s track record and stressed the opportunity to expand patient reach as awareness of Cushing’s syndrome grows. Corcept notes its focus on cortisol modulation and ongoing trials in hypercortisolism, solid tumors, ALS and liver disease; it also includes standard forward-looking statements disclaimer. Leadership transition in the Endocrinology division with a proven commercial leader could influence execution and growth in that unit.

CHMP backed approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer, based on ROSELLA Phase 2/3 data, signaling a regulatory win and potential expansion beyond Korlym. Shares surged: 90-day return 44.1%, YTD 207.6%, 5-year TSR 487.2%, underscoring momentum. Fair value cited at $141 vs $117.51 close, implying ~17% undervaluation. Catalysts include broader hypercortisolism opportunities via the CATALYST study and expected relacorilant approvals in hypercortisolism this year and ovarian cancer next year, with margin expansion possible from diversifying beyond Korlym. Risks: pricing pressure, legal challenges, or delays in relacorilant approvals. Valuation relies on a P/S multiple; trading about 15.3x sales vs peers ~5x, with fair value around 16.6x, leaving upside but elevated risk. CHMP backing and upcoming approvals could materially expand the addressable market and boost revenue and margins.

Europe's drug regulator recommended approval of relacorilant with nab-paclitaxel for platinum-resistant ovarian cancer, aligning with US guidelines. The CHMP's positive opinion on the Phase 3 ROSELLA trial (381 patients across several regions) suggests longer progression-free and overall survival with similar safety to chemotherapy. If the European Commission signs off by Q4 2026, Corcept could commercialize in Europe, expanding a market of roughly 20,000 potential candidates per year similar to the US. In the US, Lifyorli has already begun selling, generating $47.6 million in Q2 revenue on $256.1 million quarterly revenue, and Corcept raised 2026 full-year guidance to $1.1–$1.2 billion, while increasing operating expenses to fund launch and other programs. Costs and a modest pipeline risk remain as the company invests. Regulatory win in Europe could unlock a new revenue stream and accelerate Corcept's growth beyond the US.

EMA's CHMP issued a positive opinion recommending EU approval of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer. The decision, based on phase II data and the pivotal ROSELLA phase III study, showed improved progression-free survival and overall survival with the combo versus nab-paclitaxel alone, and a safety profile similar to nab-paclitaxel monotherapy. If confirmed by the European Commission, Lifyorli would join Corcept's FDA-approved label in the US (approval granted March 2026). The EU news comes as Lifyorli achieved $47.6 million in Q2 2026, its first quarter on the market. Corcept also continues other relacorilant trials (BELLA with Avastin) and has resubmitted a NDA for relacorilant to treat Cushing's syndrome, with a FDA action date targeted for Dec 17, 2026. Positive CHMP opinion could substantially expand EU sales and investor confidence ahead of the EC decision.

Corcept Therapeutics announces CHMP positive opinion recommending EU marketing authorization for Lifyorli (relacorilant). CHMP recommendation for EU approval of relacorilant opens major new market and revenue potential for Corcept.

Corcept Therapeutics Incorporated (CORT) is identified as the one growth stock set to flourish while two others are dismissed. Highlighting CORT as a top growth stock can drive investor attention and materially lift its market trajectory.

Corcept Therapeutics posted Q2 earnings as part of branded pharmaceuticals sector review, detailing financial results and market position. Q2 earnings release offers update on financial performance potentially affecting short-term stock movement.

Corcept Therapeutics beat Q2 earnings and revenue estimates while raising its 2026 outlook. Earnings beat combined with raised multi-year outlook signals materially stronger financial trajectory ahead.

Corcept Therapeutics reports record revenue in its Q2 2026 earnings call. Record revenue from the earnings call indicates strong financial results likely to drive meaningful gains in valuation and outlook.

Corcept Therapeutics reported bullish Q2 CY2026 results, prompting a 17.4% stock surge. Bullish quarterly results and sharp stock gain signal major positive shift in performance and sentiment.

Corcept Therapeutics (CORT) beat Q2 earnings and revenue estimates. Quarterly earnings beat signals moderate positive effect on near-term stock sentiment without shifting long-term trajectory.

Corcept Therapeutics Q2 earnings call covered financial results, revenue figures, pipeline progress and management outlook on operations. Q2 earnings data directly informs near-term investor sentiment and valuation for CORT.

Corcept Therapeutics reported second quarter financial results and issued a corporate update. Quarterly earnings releases and updates can shift near-term stock valuation and sentiment.

Corcept Therapeutics lifted its earnings outlook. Questions emerge on whether the stock is now overvalued. Lifting earnings outlook moderately affects financial performance expectations and market sentiment for Corcept Therapeutics.

Analysts significantly raised Corcept Therapeutics full-year earnings outlook, driving a 5.3% stock increase. Analyst earnings outlook upgrades produced a notable but limited short-term stock gain without altering core operations.

Corcept Therapeutics insider sold shares following FDA approval and a $1.05 billion outlook. FDA approval and $1.05 billion outlook represent major regulatory and financial milestones likely to reshape company trajectory.

Corcept Therapeutics resubmitted its NDA for relacorilant in Cushing's syndrome. NDA resubmission advances relacorilant toward potential approval and revenue generation in Cushing's syndrome.

Corcept Therapeutics resubmitted its New Drug Application for Relacorilant as a treatment for patients with Cushing’s Syndrome. NDA resubmission advances Relacorilant toward potential approval and revenue generation for Cushing’s Syndrome.

Positive data from Catalyst and Momentum trials boosts optimism for Corcept Therapeutics (CORT) future prospects and performance. Positive Catalyst and Momentum trials data signals major strategic progress that can significantly shift Corcept Therapeutics trajectory and investor sentiment.

CORT stock rises 42% over one month. Monthly stock surge signals noticeable positive momentum without evidence of transformative company changes.

Corcept presented new data at the ADA conference showing improved outcomes for patients with difficult-to-control type 2 diabetes and hypercortisolism treated with Korlym alongside GLP-1 therapy. Positive Korlym data at a major diabetes conference may modestly lift adoption and near-term sentiment without altering core trajectory.

Corcept Therapeutics presented new data at ASCO 2026 showing Lifyorli™ delivers overall survival across all subgroups of patients with platinum-resistant ovarian cancer, including those with recent taxane exposure. Positive survival data across subgroups for Lifyorli in ovarian cancer supports potential regulatory progress and market expansion.

Corcept Therapeutics plans to resubmit NDA for Relacorilant in Cushing's Syndrome, driving stock price higher. NDA resubmission for lead drug candidate signals major regulatory progress with direct revenue implications.

CORT stock reaches highest levels in 2026 after resubmission of NDA for Cushing’s Syndrome drug, extending five-session rally. NDA resubmission advances core Cushing’s Syndrome drug toward potential approval and fuels extended stock rally.

Corcept Therapeutics will resubmit its New Drug Application for Relacorilant to treat patients with Cushing’s Syndrome. NDA resubmission for lead candidate Relacorilant advances regulatory path toward potential approval and revenue generation.

Corcept Therapeutics (CORT) reported strong Q1 results driven by Korlym sales, raising questions about the drug's ability to sustain growth into 2026. Strong Q1 from Korlym boosts near-term financials but leaves 2026 growth uncertain, yielding moderate overall impact.

Corcept Therapeutics (CORT) shares jumped 11.9% despite a Q1 loss, driven by raised 2026 revenue outlook to $950-1,000 million and positive ALS drug data showing significant functional improvements in Phase 2 trial, prompting reassessment of the bull case. Raised 2026 guidance and positive ALS Phase 2 data signal major expansion into new therapeutic area despite Q1 loss, boosting stock and long-term prospects.

Corcept Therapeutics' Q1 results feature early Lifyorli launch and strong endocrinology momentum offsetting margin pressures. Early Lifyorli launch and endocrinology growth deliver significant strategic boost despite margin challenges.

Corcept Therapeutics (CORT) released Q1 2026 earnings call transcript detailing financial results, Korlym sales, pipeline updates including relacorilant NDA for ovarian cancer, and financial guidance. Q1 2026 earnings reveal Korlym revenue growth, NDA submission progress, and reaffirmed guidance signaling strong operational momentum and potential market expansion for CORT.